DS-2969b
DS-2969b is an orally active GyrB inhibitor with antibacterial activity. DS-2969b is is active against Clostridium difficile infection (MIC90: 0.06 μg/mL), which is 2-, 16-, and 32-fold lower than those of Fidaxomicin , Metronidazole (HY-B0318), and Vancomycin (HY-B0671), respectively. DS-2969b inhibits the supercoiling activity of C. difficile DNA gyrase. DS-2969b also exhibits activity against other Gram-positive anaerobes, including strict and facultative anaerobes. DS-2969b is safe and well tolerated in preclinical toxicology studies[1][2].
Product Specifications
CAS Number
2092352-48-0
UNSPSC
12352005
Target
Bacterial; DNA/RNA Synthesis
Related Pathways
Anti-infection; Cell Cycle/DNA Damage
Field of Research
Infection
Smiles
O=C(C1=NC(CC)=C(Cl)N1)N[C@H]2[C@@H](OC)CN(C3=NN=C(C(C)(O)C)S3)CC2
Molecular Formula
C17H25ClN6O3S
Molecular Weight
428.94
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
AKR1C4 (Aldo-keto Reductase Family 1 Member C4, 3-alpha-HSD1, 3-alpha-hydroxysteroid Dehydrogenase Type I, Chlordecone Reductase, CDR, Dihydrodiol Dehydrogenase 4, DD-4, DD4, HAKRA, CHDR) (PE)
